Oncology

Strategic Research Insights (SRI) offers extensive oncology expertise, covering a broad spectrum of solid tumors, hematological malignancies, and related cancer conditions. The firm’s research experience spans numerous therapy areas, including acute and chronic myeloid leukemia (AML, CML), myelodysplastic syndromes (MDS), breast cancer, metastatic colorectal cancer (mCRC), colon cancer, non-Hodgkin’s lymphoma (DLBCL, MCL), gastric adenocarcinoma, non-small-cell lung cancer (NSCLC), glioblastoma, prostate cancer, renal cell carcinoma, hormone refractory prostate cancer (HRPC), small-cell lung cancer (SCLC), multiple myeloma, metastatic melanoma, squamous cell carcinoma of the head and neck, and cancers requiring stem cell transplants. SRI also addresses cancer-related conditions such as febrile neutropenia, anemia due to cancer, and cancer-related emesis.

SRI’s oncology research encompasses the entire commercial planning lifecycle from discovery through Phase 2 and beyond, including product portfolio development, segmentation, valuation and targeting, positioning, and messaging optimization. SRI conducts competitive benchmarking, clinical trial investment analysis, target product profile optimization, and life cycle management. Additionally, we provide insights on global pricing, market access, reimbursement, and the design and effectiveness of direct-to-physician (DTP) and direct-to-consumer (DTC) campaigns.

Our work also includes launch sequencing, patient-centricity, ROI-based resourcing, and therapeutic area strategy to maximize commercial success across geographic regions such as the US, Canada, Europe, BRIC countries, and Asia-Pacific. We also have extensive experience in Big Data Analytics in Oncology, including predictive modeling, routine analytics, clinical patient journey, dashboarding, and several one-of-a-kind innovative projects. This comprehensive oncology expertise enables clients to make informed decisions throughout the product lifecycle with a strategic, evidence-based approach.